BVF Partners Exits XOMA Royalty Holdings in Planned $39‑Cash Deal Amid Merger, Boosting Shareholder Diversity and Short‑Term Volatility

Insider Activity Spotlight: XOMA Royalty Corp’s Recent Deal and Its Implications

The Deal in Focus On July 14, 2026, BVF Partners L P/IL and its affiliated entities – a Section 13(d) group that collectively held over 10 % of XOMA Royalty’s common stock – sold all of their holdings in a single transaction tied to the Ligand‑XOMA merger. The shares were exchanged for $39.00 in cash and contingent value rights, effectively extinguishing the group’s 100 % stake in the company. The sale coincided with XOMA’s own stock price of $40.17 and a neutral daily price change, but it drew significant social‑media attention, with a buzz score of 148 % and a positive sentiment of +26.

What This Means for Investors The liquidation of a large institutional holder can raise short‑term volatility, particularly when the shares are sold in a single block. However, the transaction was part of a structured merger and involved a clear cash payout, suggesting that the sale was pre‑planned rather than a reactive “fire‑sale.” For long‑term investors, the exit removes a sizable, potentially stabilizing shareholder from the equation, potentially increasing the weight of smaller, more active traders and institutional investors. The contingent value rights attached to the cash payment also provide a tail‑risk upside, keeping a portion of the former owners’ exposure alive in the post‑merger entity.

BVF Partners L P/IL: A Buying‑and‑Selling Pattern Historically, BVF has been a disciplined, opportunistic investor. In May 2026, the group accumulated over 3.6 million shares at $4.03 per share, building a substantial position before the merger. The subsequent sell‑off in July was executed at a 23‑point premium to the 12‑month average price, indicating a profit‑taking strategy. Earlier in the year, the group also disposed of Series X convertible preferred shares without any cash consideration, suggesting a focus on liquid common equity rather than leveraged instruments. This pattern – build, hold, and exit at a premium – aligns with a classic “buy‑low, sell‑high” play typical of value‑oriented hedge funds.

Strategic Outlook for XOMA With the merger complete and the institutional stake removed, XOMA’s shareholder base is expected to become more diversified. The company’s core business model – acquiring royalty rights for pre‑commercial biotech candidates – remains unchanged, and the 56.49 % year‑over‑year gain in stock price indicates market optimism about future revenue streams. Nonetheless, the removal of a major shareholder may amplify short‑term price swings until the new ownership structure stabilizes. For investors, this transition period offers an opportunity to reassess valuation multiples; the current P/E of 25.49 sits comfortably above the biotech average but below the sector’s 35‑plus range, hinting at potential upside if the company can convert its royalty pipeline into steady cash flows.

Key Takeaway BVF Partners L P/IL’s exit reflects a calculated, profitable trade rather than distress. While the removal of a large shareholder can briefly unsettle the market, XOMA’s robust business model and positive sentiment suggest that the company is positioned to continue delivering incremental value. Investors should monitor the company’s royalty pipeline disclosures and the performance of the newly acquired contingent value rights, which may provide additional upside in the post‑merger era.